Giuseppe Curigliano: Excited to see NBC News highlight the groundbreaking results of DESTINY-06
Giuseppe Curigliano reposted on LinkedIn, adding: .
“Excited to see NBC News highlight the groundbreaking results of DESTINY-06 following its presentation at ASCO2024!
This timely coverage underscores the impact of our work in advancing cancer treatment. Thank you for bringing this story to the forefront!”
Quoting
“Very timely article on ADCs (Antibody-drug conjugates) today in NBC News after DB06 presentation by Giuseppe Curigliano this morning.
Honored to have contributed to get the word out about how these drugs are changing our field!”
Further details.
Source: Giuseppe Curigliano/LinkedIn and Erika Hamilton/LinkedIn
Giuseppe Curigliano, MD, PhD, is the Director of the Early Drug Development Division and co-chairs the Experimental Therapeutics Program at the European Institute of Oncology. He is a member of the Department of Oncology and Hemato-Oncology’s steering committee at the University of Milan and serves on the Italian National Health Council, advising the Ministry of Health on cancer policy issues.
Erika Hamilton is a medical oncologist and the Director of Breast Cancer and Gynecologic Cancer Research at Sarah Cannon Research Institute (USA). In her role, Dr. Hamilton oversees the research program and clinical trial menu for gynecologic and breast cancer from a medical oncology perspective.
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023